Kairos Pharma, Ltd.

What they do

Kairos Pharma is developing therapeutics for prostate, lung, breast cancer, and glioblastoma, targeting mechanisms of therapeutic resistance and immune suppression. Its portfolio includes five in-house candidates and two therapeutic agents from its Enviro Therapeutics subsidiary, including ENV 105, which is in Phase 1 (non-small cell lung cancer) and Phase 2 (prostate cancer) trials, and ENV 205, a pre-clinical antibody for chemotherapy resistance and cachexia. The company licenses its proprietary technologies from Cedars-Sinai Medical Center.

Revenue drivers

• No approved products — The company has not generated any revenue from product sales and does not expect to until clinical trials are completed and regulatory approval is obtained.
• ENV 105 (clinical-stage) — In Phase 1 for non-small cell lung cancer and Phase 2 for prostate cancer; designed to address resistance to chemotherapy, radiation, androgen-targeted therapy, EGFR inhibitors, or checkpoint inhibition.
• ENV 205 (pre-clinical) — Antibody technology for depleting mitochondrial DNA from circulation, intended for chemotherapy resistance and cachexia; no revenue expected near-term.
• Other pipeline candidates — Includes additional preclinical or clinical-stage drug candidates targeting immune response, but no revenue is currently generated from these.

Recent performance

Net losses widened from $1.8M in 2023 to $2.6M in 2024 and $5.4M in 2025, with diluted EPS of -$0.17, -$0.23, and -$0.30 respectively. Operating cash flow swung from $81,000 in 2023 to -$4.0M in 2024 and -$3.4M in 2025. For the six months ended June 30, 2026, the company reported a net loss of $3.0M (unaudited) versus $2.7M in the same period of 2025, and an accumulated deficit of $17.3M. As of June 30, 2026, total assets were $4.5M, cash and equivalents $2.6M, and shareholder equity $4.2M.

Strategy

Management plans to advance the current pipeline through preclinical and clinical development, manufacture drug product, seek regulatory approval, and expand intellectual property. The company aims to finance operations through public or private equity offerings, debt, and potential collaborations, strategic alliances, or licensing arrangements. It expects to continue incurring significant operating losses and requires substantial additional funding to support growth and commercialization efforts.

Risks

• No approved products or revenue — The company has not generated any product revenue and may never obtain regulatory approval or commercialize any candidate.
• Substantial capital needs — Management states it will need significant additional funding to continue operations and may be unable to raise funds on acceptable terms or at all.
• Clinical and regulatory uncertainty — All product candidates are in preclinical or clinical stages and are subject to the inherent risks of failure, delay, or non-approval by the FDA.
• Dependence on licensed technology — Core proprietary technologies are licensed from Cedars-Sinai Medical Center, creating potential risks related to license maintenance and rights.

Outlook

Management expects to continue incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its pipeline and builds capabilities. The company will not generate product revenue unless and until it completes clinical trials and gains regulatory approval, likely requiring partnerships or further financing. No forward-looking guidance on timelines or milestones was provided in the latest filings.